Microba Life Sciences (FRA:F3Y) Stock Based Compensation: €0.00 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:F3Y Microba Life Sciences Ltd FRA:F3Y
29 GF Score
Price €0.02
GF Value €0.12
! 6 Warning Signs
View Full Analysis

What is Microba Life Sciences Stock Based Compensation?

Microba Life Sciences FRA:F3Y 29 Stock Based Compensation is €0.00 Mil as of Dec. 2025. GuruFocus rates FRA:F3Y with a GF Score™ of 29/100 and a GF Value™ of €0.12. The stock has 6 warning signs investors should review.

Microba Life Sciences's Stock Based Compensation for the six months ended in Dec. 2025 was €0.00 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2025 was €0.00 Mil.

Microba Life Sciences Stock Based Compensation Related Terms

Microba Life Sciences Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Microba Life Sciences's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Microba Life Sciences Stock Based Compensation Chart

Microba Life Sciences Annual Data
Trend Jun22 Jun23 Jun24 Jun25
Stock Based Compensation
0.00 0.00 0.00 0.00

Microba Life Sciences Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:F3Y
29GF Score
Microba Life Sciences Ltd FRA:F3Y
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Microba Life Sciences Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.00 Mil.

What does a Stock Based Compensation of €0.00 Mil mean?
Microba Life Sciences (FRA:F3Y) has a Stock Based Compensation of €0.00 Mil as of Dec. 2025. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Microba Life Sciences and its competitors.
Is Microba Life Sciences' Stock Based Compensation too high?
Microba Life Sciences' current Stock Based Compensation is €0.00 Mil. Overall, Microba Life Sciences has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Microba Life Sciences' Stock Based Compensation compare to TMO and DHR?
Microba Life Sciences' Stock Based Compensation of €0.00 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Medical Diagnostics & Research company?
A good Stock Based Compensation depends on the Medical Diagnostics & Research industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Microba Life Sciences and its competitors. Microba Life Sciences's current Stock Based Compensation is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Microba Life Sciences stock overvalued right now?
Microba Life Sciences (FRA:F3Y) has a current Stock Based Compensation of €0.00 Mil. The stock's GF Value™ is €0.12, compared to a current price of €0.02 — trading 81.3% below its estimated fair value. The current Stock Based Compensation is €0.00 Mil. Microba Life Sciences' overall GF Score™ is 29/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Microba Life Sciences (FRA:F3Y), the current Stock Based Compensation is €0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Microba Life Sciences (FRA:F3Y) Overvalued in 2026?

Based on GuruFocus' analysis, Microba Life Sciences stock appears to be undervalued. The current stock price of €0.02 is trading 81.3% below its estimated GF Value™ of €0.12.

Key valuation signals for FRA:F3Y:

  • Stock Based Compensation: €0.00 Mil
  • GF Value™: €0.12 vs. price of €0.02 (81.3% below fair value)
  • GF Score™: 29/100 with 6 warning signs

No single metric tells the full story. See the FRA:F3Y stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Microba Life Sciences Business Description

Other Exchanges MAP:Australia
Address 324 Queen Street, Level 10, Brisbane, QLD, AUS, 4000
Microba Life Sciences Ltd is a commercial-stage company with technology for measuring the human gut microbiome and engages in providing gut microbiome testing services globally to consumers, clinicians, and researchers. It is also involved in developing new pathology services, therapeutics, and diagnostics based on the human gut microbiome. The company's operating segments are: Testing Services and Supplements, which derive key revenue, and Research and Development. Geographically, the company derives maximum revenue from Australia and the rest from Europe, New Zealand, the United States, Asia, and other regions.
29GF Score

Get the complete analysis for FRA:F3Y

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.02
Price
€0.12
GF Value